Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.

Abstract: The present invention relates to an antibody, or an antigen-binding fragment thereof, specifically binding to APRIL for use in the prevention and/or treatment of hypertriglyceridemia, metabolic syndrome, non-alcoholic steatohepatitis, diabetes mellitus type 2, abdominal aortic aneurysm, atherogenic dyslipidemia, cardiovascular events (e.g., myocardial infarction and stroke) and/or atherosclerosis. The invention further relates to a polynucleotide that encodes and/or a pharmaceutical composition that comprises the antibody or an antigen-binding fragment of the invention. The invention also relates to a kit and/or method for quantifying the concentration of nc-APRIL, canonical APRIL or total APRIL in a sample. Further, the invention relates to a nephelometric assay for quantifying nc-APRIL.

Abstract: The invention relates to a fan blade (3) made of composite material the fibrous reinforcement of which comprises first strands (12) having a first stiffness, second strands (13) having a second stiffness and third strands (14) having a third stiffness lower than the first stiffness and greater than the second stiffness, the blade comprising a first portion (15) comprising only first strands (12), a second portion (16) comprising only second strands (13) and a third portion (17) which is located between the first and second portions (15, 16) and which comprises both first, second and third strands (12, 13, 14); there is a gradual transition of properties at the interface between the different portions (15, 16, 17).

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.

Abstract: A sprue system for a nozzle-side injection-molding arrangement of an injection-molding machine for introducing a plasticizable and/or plasticized plastics material into an injection-molding tool along a runner, the center axis of which fixes an injection axis, includes a sprue piece which at least partially forms the runner, a tube portion and a flange portion. A fastener assembly for fastening the sprue system to the injection-molding tool and for aligning the sprue piece along the injection axis is included. The sprue piece and the fastener assembly are formed adjustably in relation to one another and the sprue system has an adjuster for setting a distance (A) between the flange portion and the fastener assembly.

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.

Abstract: A sprue system for a nozzle-side injection-molding arrangement of an injection-molding machine for introducing a plasticizable and/or plasticized plastics material into an injection-molding tool along a runner, the center axis of which fixes an injection axis, includes a sprue piece which at least partially forms the runner, a tube portion and a flange portion. A fastener assembly for fastening the sprue system to the injection-molding tool and for aligning the sprue piece along the injection axis is included. The sprue piece and the fastener assembly are formed adjustably in relation to one another and the sprue system has an adjuster for setting a distance (A) between the flange portion and the fastener assembly.

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Abstract: The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.

Abstract: The present invention relates to the preparation of substantially purified anti-EDA1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of EDA1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles. The anti-EDA1 antibodies are also useful in immunoassays such as sandwich ELISA.

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Abstract: The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.

Abstract: The invention relates to pharmaceutical compositions and methods for the treatment of ectodermal displasias via the administration of EDA agonists, in particular EDI200. Use of the compositions and methods described allow for therapeutic dosing and administration regimens in human patients to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.